XR-5000

• CAT Number: I010109
• CAS Number: 89459-25-6
• Molecular Formula: C18H19N3O
• Molecular Weight: 293.37
• Purity: ≥95%
• Synonyms: CRC-8805; DACA; NSC-601316; SN-22995; XR-5000; CRC8805; NS-601316; SN22995; XR5000.;N-(2-(Dimethylamino)ethyl)-4-acridinecarboxamide
• Target: topoisomerase I and II inhibitor
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
• InChI: InChI=1S/C18H19N3O/c1-21(2)11-10-19-18(22)15-8-5-7-14-12-13-6-3-4-9-16(13)20-17(14)15/h3-9,12H,10-11H2,1-2H3,(H,19,22)
• InChIKey: XBGNERSKEKDZDS-UHFFFAOYSA-N
• SMILES: CN(C)CCNC(=O)C1=CC=CC2=CC3=CC=CC=C3N=C21

XR-5000(CAT: I010109) (also known as DACA or SN 22995) is a dual inhibitor of DNA topoisomerase I and II, enzymes essential for DNA transcription, replication, and repair. By targeting both enzymes, XR-5000 effectively disrupts DNA processes critical for tumor cell survival, leading to apoptosis. This dual inhibition is particularly valuable in oncology research, supporting studies on colorectal cancer, glioblastoma, and other malignancies. Unlike traditional single-enzyme inhibitors, XR-5000 represents a novel therapeutic approach by combining the effects on both topoisomerases, enhancing its anticancer efficacy. It is a crucial tool for exploring innovative cancer treatments and understanding the mechanisms underlying topoisomerase-targeting drugs.